Should I Buy FULC? FULC 2026 Analysis

Should You Buy Fulcrum Therapeutics Inc (FULC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

9.740

1 Day change

1.99%

52 Week Range

15.740

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: price broke below near-term support (around 9.93) after a sharp -6% regular-session drop, with momentum still deteriorating.
For an impatient buyer, the odds favor further drift lower near-term (pattern-based projection: -0.85% 1-week, -3.36% 1-month), so the risk/reward is not attractive today.
A better “buy-now” setup would require a quick reclaim of the pivot (~10.55) and stabilization; until then, this is a HOLD / avoid-new-entry.

Technical Analysis

Trend/momentum: MACD histogram is negative (-0.0193) and expanding lower → bearish near-term momentum.
RSI: RSI(6) at ~29.2 → near oversold; bounce is possible, but oversold alone is not a confirmation of reversal.
Moving averages: SMA_5 > SMA_20 > SMA_200 is bullish structurally, but current price action is a pullback within that broader uptrend.
Levels: Pivot 10.549 (key reclaim level). Support S1 9.932 has been lost post-market (9.89), next support S2 9.551. Resistance: 11.166 then 11.547.
Probability/trend model: similar-pattern study implies a slight negative bias across next day/week/month.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Put/Call OI ratio 0.16 → call-heavy open interest (bullish leaning in positioning).
Flow: Option volume is extremely light (only 2 calls, 0 puts) → sentiment from today’s flow is not very informative.
Volatility: 30D IV ~130% vs historical vol ~59.7% → options are pricing very large moves; IV is lower than the 5D/10D IV averages, suggesting some recent vol cooling but still elevated.
Activity: “Today vs OI avg 30D” shows a very large spike, but with tiny volume, treat as less reliable for strong sentiment conclusions.

Technical Summary

Sell

Buy

Positive Catalysts

- Clinical narrative remains the core upside driver: multiple firms cited encouraging Phase 1b PIONEER data (dose-response and HbF improvement) and expect additional 12-week data in Q1 2026 plus FDA discussions for a registrational path.
- Competitive backdrop improved previously (Agios RISE UP failure referenced by analysts), reinforcing the market opportunity perception in SCD.
- Upcoming event: QDEC 2025 earnings on 2026-03-04 (pre-market) can act as a sentiment/catalyst point, though the main driver is still clinical/regulatory updates.

Neutral/Negative Catalysts

- No fresh news in the last week to explain/support a reversal after the sharp selloff; the drop is currently being “confirmed” by weakening momentum (MACD).
- High implied volatility (30D ~130%) implies the market expects big swings; near-term downside can persist if price fails to regain 10.55 pivot quickly.
- Options volume is too low today to confirm dip-buying conviction.
- Hedge funds/insiders: both described as neutral recently, offering no supportive “smart money” tailwind in the near term.
- No recent congress trading data available (no influential buying/selling signal).

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0 (no YoY growth; effectively pre-commercial).
Profitability: Net income fell to -$19.595M (worse by ~9.68% YoY) and EPS declined to -$0.31 (worse by ~11.43% YoY) → losses widening.
Gross margin: dropped to 0 (down -100% YoY), consistent with a development-stage profile and lack of product revenue.
Bottom line: fundamentals are still “clinical-stage biotech” dependent on trial/regulatory progress rather than operating growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend is strongly upward on price targets (mostly in Dec 2025) following encouraging PIONEER updates: Truist to $18 (Buy), RBC to $10 (Sector Perform), Cantor to $24 (Overweight), Stifel to $25 (Buy), H.C. Wainwright to $25 (Buy), Piper to $23 (Overweight).
Notable dissent: BofA remains Underperform (PT to $7), highlighting meaningful skepticism on valuation/probability-of-success even after data.
Wall Street pros: multiple Buy/Overweight ratings, repeated PT raises, and optimism around dose-response/HbF induction and path toward registrational discussions.
Wall Street cons: at least one major underperform view; commercialization is far out (some models assume ~2029 launch), and the story remains highly event-driven with financial losses continuing.

10 Analyst Rating

Wall Street analysts forecast FULC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FULC is 16.8 USD with a low forecast of 7 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

1 Sell

Moderate Buy

Current: 9.550

Low

Averages

16.8

High

Current: 9.550

Low

Averages

16.8

High

Truist

Buy

maintain

$14 -> $18

AI Analysis

2025-12-11

Reason

Truist

Price Target

$14 -> $18

AI Analysis

2025-12-11

maintain

Buy

Reason

Truist raised the firm's price target on Fulcrum Therapeutics to $18 from $14 and keeps a Buy rating on the shares. Positive reception is persisting around the cohort 4 data from the phase 1b PIONEER study for pociredir in sickle cell disease, SCD, which came in as a win for the company, the analyst tells investors in a research note.

BofA

Underperform

maintain

$6 -> $7

2025-12-09

Reason

BofA

Price Target

$6 -> $7

2025-12-09

maintain

Underperform

Reason

BofA raised the firm's price target on Fulcrum Therapeutics to $7 from $6 and keeps an Underperform rating on the shares after the company presented partial Cohort 4 data at ASH from its ongoing Phase 1b PIONEER study assessing pociredir in severe sickle cell disease. The firm assumes a potential 2029 launch in SCD with $1.5B in nominal peak sales by 2038, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FULC

Unlock Now

FULC Should I Buy

FULC Should I Buy

Should You Buy Fulcrum Therapeutics Inc (FULC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch